Falcon's Beyond Appoints Saham Ali as Chief Technology Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Falcon's Beyond announced the promotion of Saham Ali to the newly created role of chief technology officer. Ali, formerly executive VP of technology, will implement technology strategies and innovation across the company. As chief technology officer, he will continue to lead initiatives that will have the potential to advance the Company's product offerings in areas such as real-time rendering, robotics, ride systems, extended reality, generative AI, AI-driven personalization, and connected experiences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FBYD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FBYD
About FBYD
Falcon’s Beyond Global, Inc. is engaged in innovative and immersive storytelling. The Company propels intellectual property (IP) activations across physical and digital experiences through three core business units: Falcon’s Creative Group (FCG), Falcon’s Beyond Destinations (FBD), and Falcon’s Beyond Brands (FBB). FCG creates master plans, designs attractions and experiential entertainment, and produces content, interactives and software. FBD develops a diverse range of entertainment experiences using both owned and third-party licensed intellectual property, consisting of Producciones de Parques, S.L. (PDP), and Destinations Operations, which develops a diverse range of entertainment experiences using both Company owned, and third-party licensed intellectual property, spanning location-based entertainment, dining, and retail. FBB brings brands and intellectual property to life through animation, movies, licensing and merchandising, gaming, as well as ride and technology sales.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Falcon's Beyond (FBYD) Stock Rallies 15% Amid Ongoing Liquidity Concerns
- Stock Rebound: Falcon's Beyond's stock surged 15% on Friday, closing at $6.96, despite a prior streak of 11 consecutive down days, indicating cautious optimism from the market regarding its future prospects.
- Long-term Decline: Even with Friday's rebound, FBYD has fallen 59% since its close on December 29, reflecting ongoing liquidity challenges and a lack of market confidence in the company.
- Financial Management Concerns: Analyst Bashar Issa highlighted that Falcon's Beyond's poor financial management could lead to disappointing investment returns, although he noted potential surprises from the Creative Group as Qiddiya theme park projects progress.
- Cautious Investment Advice: Issa advises investors to watch FBYD but not rush to buy, indicating a cautious market sentiment regarding the company's future performance, especially with unresolved liquidity issues.
Continue Reading
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
Continue Reading